Stockscreener 앱 받기
76.54
0.09%
-0.90
전일 마감가:
$75.64
열려 있는:
$76
하루 거래량:
104.71K
Relative Volume:
0.07
시가총액:
$6.13B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-12.89
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-1.74%
1개월 성능:
+0.36%
6개월 성능:
+47.42%
1년 성능:
+62.97%
1일 변동 폭
$75.14
$76.37
1주일 범위
$73.09
$76.95
52주 변동 폭
$35.95
$87.50
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
76.37 | 6.07B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.92 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.00 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
842.75 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.06 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.73 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Squarepoint Ops LLC Grows Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Armistice Capital LLC Has $231.28 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - BioSpace
Marshall Wace LLP Reduces Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Raised by Hood River Capital Management LLC - MarketBeat
Emma Reeve Sells 733 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Can PTC Therapeutics Inc. (BH3) stock sustain breakout momentumShare Buyback & Weekly Watchlist for Consistent Profits - Newser
Russell Investments Group Ltd. Buys 118,105 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
How higher bond yields impact PTC Therapeutics Inc. (BH3) stock2025 Price Action Summary & Step-by-Step Trade Execution Guides - Newser
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $271,051.96 in Stock - MarketBeat
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - AOL.com
Why PTC Therapeutics Inc. stock could rally in 2025Inflation Watch & Target Return Focused Picks - Newser
Will PTC Therapeutics Inc. (BH3) stock outperform global peers2025 Analyst Calls & Entry Point Strategy Guides - Newser
PTC Therapeutics (NASDAQ:PTCT) Shares Down 5.6%Time to Sell? - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Panagora Asset Management Inc. Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT): Revisiting Valuation After Strong Multi‑Year Share Price Gains - Yahoo Finance
PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs - The Globe and Mail
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - Nasdaq
PTC Therapeutics downgraded at RBC as Sephience sales priced in - MSN
PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says - marketscreener.com
Prudential Financial Inc. Has $4.12 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics stock price target raised to $55 from $50 at Goldman Sachs - Investing.com UK
Legal & General Group Plc Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - marketscreener.com
Can PTC Therapeutics Inc. (BH3) stock retain market dominance2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
How PTC Therapeutics Inc. (BH3) stock moves on employment dataQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
Is PTC Therapeutics Inc. stock a buy for dividend growth2025 Trading Recap & Reliable Volume Spike Trade Alerts - Newser
Why PTC Therapeutics Inc stock could rally in 2025Weekly Earnings Recap & Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividendsPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Finviz
PTC Therapeutics Shares Drop After RBC Downgrade - marketscreener.com
PTC Therapeutics downgraded at RBC as Sephience sales priced in (PTCT:NASDAQ) - Seeking Alpha
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - The Manila Times
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
PTC Therapeutics stock downgraded by RBC Capital as shares near fair value - Investing.com Canada
RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82 - marketscreener.com
(PTCT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Elo Mutual Pension Insurance Co Makes New $689,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation - Yahoo Finance
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Globe and Mail
Advantage Alpha Capital Partners LP Invests $204,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
PTC 테라퓨틱스 주식 (PTCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Reeve Emma | Director |
Dec 03 '25 |
Sale |
78.62 |
733 |
57,628 |
6,666 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Dec 02 '25 |
Sale |
79.07 |
3,428 |
271,052 |
349,964 |
0.56%
1.23%
자본화:
|
볼륨(24시간):